326 related articles for article (PubMed ID: 18369088)
21. [Endometrial carcinoma and precursor lesions].
Djordjević B; Stanojević Z
Srp Arh Celok Lek; 2007; 135(3-4):230-4. PubMed ID: 17642468
[TBL] [Abstract][Full Text] [Related]
22. A candidate precursor to serous carcinoma that originates in the distal fallopian tube.
Lee Y; Miron A; Drapkin R; Nucci MR; Medeiros F; Saleemuddin A; Garber J; Birch C; Mou H; Gordon RW; Cramer DW; McKeon FD; Crum CP
J Pathol; 2007 Jan; 211(1):26-35. PubMed ID: 17117391
[TBL] [Abstract][Full Text] [Related]
23. Expression of immunoreactivity and genetic mutation in eosinophilic and ciliated metaplastic changes of endometrial glandular and stromal breakdown: cytodiagnostic implications.
Shimizu K; Norimatsu Y; Kobayashi TK; Sakurai M; Ogura S; Yoshizawa A; Miyamoto T; Miyake Y; Aratake Y; Sakaguchi T; Ohno E
Ann Diagn Pathol; 2009 Apr; 13(2):89-95. PubMed ID: 19302956
[TBL] [Abstract][Full Text] [Related]
24. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.
Kindelberger DW; Lee Y; Miron A; Hirsch MS; Feltmate C; Medeiros F; Callahan MJ; Garner EO; Gordon RW; Birch C; Berkowitz RS; Muto MG; Crum CP
Am J Surg Pathol; 2007 Feb; 31(2):161-9. PubMed ID: 17255760
[TBL] [Abstract][Full Text] [Related]
25. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
[TBL] [Abstract][Full Text] [Related]
26. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma.
Salvador S; Rempel A; Soslow RA; Gilks B; Huntsman D; Miller D
Gynecol Oncol; 2008 Sep; 110(3):408-17. PubMed ID: 18597838
[TBL] [Abstract][Full Text] [Related]
27. [Analysis of p53, MDR-1, and GST-pi expression in endometrial carcinoma].
Todo Y
Hokkaido Igaku Zasshi; 2003 Mar; 78(2):117-27. PubMed ID: 12704854
[No Abstract] [Full Text] [Related]
28. [A study on expression of tumor suppressor gene p53 in endometrial carcinoma].
Xue F; Jiao S; Zhao F
Zhonghua Fu Chan Ke Za Zhi; 1995 Nov; 30(11):647-50. PubMed ID: 8745486
[TBL] [Abstract][Full Text] [Related]
29. Overexpression and mutation of p53 in endometrial carcinoma.
Kohler MF; Berchuck A; Davidoff AM; Humphrey PA; Dodge RK; Iglehart JD; Soper JT; Clarke-Pearson DL; Bast RC; Marks JR
Cancer Res; 1992 Mar; 52(6):1622-7. PubMed ID: 1540970
[TBL] [Abstract][Full Text] [Related]
30. p53 gene status in endometrial carcinomas showing diffuse positivity for p53 protein by immunohistochemical analysis.
Ambros RA; Ross JS; Kallakury BV; Malfetano J; Kim Y; Hwang J; Breese K; Figge J
Mod Pathol; 1995 May; 8(4):441-5. PubMed ID: 7567946
[TBL] [Abstract][Full Text] [Related]
31. Insights into endometrial serous carcinogenesis and progression.
Fadare O; Zheng W
Int J Clin Exp Pathol; 2009; 2(5):411-32. PubMed ID: 19294001
[TBL] [Abstract][Full Text] [Related]
32. Molecular analysis in endometrial cancer.
Caduff RF; Svoboda-Neumann SM; Johnston CM; Bartos RE; Frank TS
Verh Dtsch Ges Pathol; 1997; 81():219-27. PubMed ID: 9474873
[TBL] [Abstract][Full Text] [Related]
33. MMP-2, TIMP-1, E-cadherin, and beta-catenin expression in endometrial serous carcinoma compared with low-grade endometrial endometrioid carcinoma and proliferative endometrium.
Shaco-Levy R; Sharabi S; Piura B; Sion-Vardy N
Acta Obstet Gynecol Scand; 2008; 87(8):868-74. PubMed ID: 18607832
[TBL] [Abstract][Full Text] [Related]
34. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis.
Tashiro H; Isacson C; Levine R; Kurman RJ; Cho KR; Hedrick L
Am J Pathol; 1997 Jan; 150(1):177-85. PubMed ID: 9006334
[TBL] [Abstract][Full Text] [Related]
35. Mixed serous carcinoma of the endometrium with trophoblastic differentiation: analysis of the p53 tumor suppressor gene suggests stem cell origin.
Horn LC; Hänel C; Bartholdt E; Dietel J
Ann Diagn Pathol; 2008 Feb; 12(1):1-3. PubMed ID: 18164407
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical and in situ hybridization analysis of p53 in human endometrial carcinoma of the uterus.
Jiko K; Sasano H; Ito K; Ozawa N; Sato S; Yajima A
Anticancer Res; 1993; 13(2):305-10. PubMed ID: 8517643
[TBL] [Abstract][Full Text] [Related]
37. Endometrial eosinophilic syncytial change related to breakdown: immunohistochemical evidence suggests a regressive process.
Shah SS; Mazur MT
Int J Gynecol Pathol; 2008 Oct; 27(4):534-8. PubMed ID: 18753967
[TBL] [Abstract][Full Text] [Related]
38. p53 Mutation analysis of low-grade dysplasia and high-grade dysplasia/carcinoma in situ of the esophagus using laser capture microdissection.
Kobayashi M; Kawachi H; Takizawa T; Uchida K; Sekine M; Kumagai J; Momma K; Nemoto T; Akashi T; Funata N; Eishi Y; Koike M
Oncology; 2006; 71(3-4):237-45. PubMed ID: 17652955
[TBL] [Abstract][Full Text] [Related]
39. Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum.
Hashi A; Yuminamochi T; Murata S; Iwamoto H; Honda T; Hoshi K
Int J Gynecol Pathol; 2003 Oct; 22(4):374-7. PubMed ID: 14501819
[TBL] [Abstract][Full Text] [Related]
40. Wilms' tumor gene 1 (WT1) in endometrial carcinoma.
Coosemans A; Moerman P; Verbist G; Maes W; Neven P; Vergote I; Van Gool SW; Amant F
Gynecol Oncol; 2008 Dec; 111(3):502-8. PubMed ID: 18929401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
